Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Myy dad was diagnosed with small cell lung cancer in Aug. 2017. He received the cisplatin/etoposide chemo and 30 days of radiation. He finished...
Husband diagnosed with stage 4 lung cancer, 4 rounds chemo, then tarceva targeted therapy for 14 months. Recently has rapidly experienced mental...
My father has an EGFR exon 20 insertion mutation. We found out today that the PD-L1 was 60% which apparently is rare for an exon 20 insertion, but it...
Hi everyone, My mom just had lobectomy two weeks ago. From her pre-surgery PET scan, hilum lymph nodes on both side and mediastinal lymph nodes were...
Today we celebrate the birthday of two of the most important people in the GRACE community, Dr Jack West and Dr. Jared Weiss, A little over ten years...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.